Compare BioNTech SE - ADR (BNTX) vs iShares Core S&P 500 ETF (IVV) Price & Performance

BioNTech SE - ADRTrade

iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs iShares Core S&P 500 ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while iShares Core S&P 500 ETF trades at $757.33. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

	BNTX	IVV
Market Cap	$22.86B	—
Sector	Health	Broad Market / Factor
52-Week High	$119.34	$763.10
52-Week Low	$83.89	$624.65
Enterprise Value	$6.53B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

iShares Core S&P 500 ETF

IVV trades at $752.57, down 0.77% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF approaches key resistance near $756-$760 with support at $750-$745. Recent news highlights ongoing AI-driven market dynamics and analyst optimism for S&P 500 targets reaching 8,000+ by year-end, though concerns about valuation and earnings season catalysts persist.

The outlook remains positive with strong institutional sentiment and technical momentum, but stretched valuations and potential market volatility present near-term risks. Earnings season performance will be critical for sustaining the current rally toward record highs.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BNTX

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.Na · 1 day agoBullish View details →

IVV

Invesco S&P 500 Equal Weight ETF underperforms cheaper cap-weighted funds due to fees, cash drag, and rebalancing costs.24/7 Wall Street · 1 day agoBearish Markets hit highs amid historic overvaluation and record margin debt in H1 2026, signaling caution ahead.ETF Trends · 2 days agoNeutral S&P 500 nears record high with 1.3% weekly gain, up 10.7% YTD in 2026.ETF Trends · 4 days agoNeutral View details →

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.